myrwdРеальная клиническая практика: данные и доказательстваReal-World Data & Evidence2782-3784Publishing House OKI10.37489/2782-3784-myrwd-057FKIIZZmyrwd-79Research ArticleОЦЕНКА ТЕХНОЛОГИЙ ЗДРАВООХРАНЕНИЯHEALTH TECHNOLOGY ASSESSMENTОбзор методов оценки экономической эффективности медицинских вмешательствReview of methods for assessing the cost-effectiveness of medical interventionshttps://orcid.org/0009-0003-4992-559XБушеваТ. И.BushevaT. I.

Бушева Татьяна Игоревна — Ординатор кафедры клинической фармакологи и доказательной медицины

Санкт-Петербург 

Tatiana I. Busheva — resident of the department of Clinical Pharmacology and Evidence-Based Medicine

St. Petersburg

boushewa@mail.ruhttps://orcid.org/0000-0003-3031-4572КурылевА. А.KurylevA. A.

Курылев Алексей Александрович — к. м. н., доцент кафедры клинической фармакологии и доказательной медицины ; ФГБУ «Национальный исследовательский центр онкологии им. Н. Н. Петрова»

Санкт-Петербург 

Alexey A. Kurylev — Cand. Sci. (Med.), associate professor Department of Clinical Pharmacology and Evidence-Based Medicine; National Research Center of Oncology named after N. N. Petrov

St. Petersburg

alexey-kurilev@yandex.ruФГБОУ ВО «Первый Санкт-петербургский государственный медицинский университет имени И. П. Павлова»РоссияFirst Saint Petersburg State Medical University named after I. P. PavlovRussian Federation20243012202444310Copyright © Бушева Т.И., Курылев А.А., 20252025Бушева Т.И., Курылев А.А.Busheva T.I., Kurylev A.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.myrwd.ru/jour/article/view/79

Определение эффективности лекарственного препарата — сложный процесс. В настоящее время стандартным методом определения эффективности использования медицинского вмешательства является «год жизни с поправкой на качество» (QALY; quality adjusted life-years). Летом 2024 было опубликовано описание нового метода оценки эффективности медицинских вмешательств — SoLV (Standard of Living Valuation; оценка исходя из уровня жизни). Этот недавно разработанный метод сложнее, чем QALY, но возможности его шире. Однако этот метод так же не является исчерпывающим. Проблема создания оптимального метода оценки экономической эффективности технологий здравоохранения остаётся открытой.

Assessment of the effectiveness of a drug is a complex process. Currently, the standard method for assessing the effectiveness of a medical intervention is the quality-adjusted life years (QALY). In the summer of 2024, a description of a new method for assessing the effectiveness of medical interventions — Standard of Living Valuation (SoLV) was published. The proposed method is more difficult than QALY, but its capabilities are broader. However, this method is also not optimal. The problem of creating an optimal method for assessing the cost-effectiveness of health technologies remains open.

исследования реальной клинической практикиоценка технологий здравоохраненияQALYSoLVRWEhealth technology assessmentQALYSoLVReferencesInstitute for Clinical and Economic Review. 20202023 Value Assessment Framework. 1–76. 2020.Institute for Clinical and Economic Review. 20202023 Value Assessment Framework. 1–76. 2020.Pyenson B, Smith R, Halpren A, Entezarian P. Millman Report. A new framework for quantifying healthcare value using real-world evidence, 1-18. 2024 aug.Pyenson B, Smith R, Halpren A, Entezarian P. Millman Report. A new framework for quantifying healthcare value using real-world evidence, 1-18. 2024 aug.Spencer A, Rivero-Arias O, Wong R, Tsuchiya A, Bleichrodt H, Edwards RT, Norman R, Lloyd A, Clarke P. The QALY at 50: One story many voices. Soc Sci Med. 2022 Mar;296:114653. doi: 10.1016/j.socscimed.2021.114653.Spencer A, Rivero-Arias O, Wong R, Tsuchiya A, Bleichrodt H, Edwards RT, Norman R, Lloyd A, Clarke P. The QALY at 50: One story many voices. Soc Sci Med. 2022 Mar;296:114653. doi: 10.1016/j.socscimed.2021.114653.Kim YE, Jung YS, Ock M, Yoon SJ. DALY Estimation Approaches: Understanding and Using the Incidence-based Approach and the Prevalence-based Approach. J Prev Med Public Health. 2022 Jan;55(1):10-18. doi: 10.3961/jpmph.21.597.Kim YE, Jung YS, Ock M, Yoon SJ. DALY Estimation Approaches: Understanding and Using the Incidence-based Approach and the Prevalence-based Approach. J Prev Med Public Health. 2022 Jan;55(1):10-18. doi: 10.3961/jpmph.21.597.Rios-Diaz AJ, Lam J, Ramos MS, Moscoso AV, Vaughn P, Zogg CK, Caterson EJ. Global Patterns of QALY and DALY Use in Surgical Cost-Utility Analyses: A Systematic Review. PLoS One. 2016 Feb 10;11(2):e0148304. doi: 10.1371/journal.pone.0148304.Rios-Diaz AJ, Lam J, Ramos MS, Moscoso AV, Vaughn P, Zogg CK, Caterson EJ. Global Patterns of QALY and DALY Use in Surgical Cost-Utility Analyses: A Systematic Review. PLoS One. 2016 Feb 10;11(2):e0148304. doi: 10.1371/journal.pone.0148304.Rand LZ, Melendez-Torres GJ, Kesselheim AS. Alternatives to the quality-adjusted life year: How well do they address common criticisms? Health Serv Res. 2023 Apr;58(2):433-444. doi: 10.1111/1475-6773.14116.Rand LZ, Melendez-Torres GJ, Kesselheim AS. Alternatives to the quality-adjusted life year: How well do they address common criticisms? Health Serv Res. 2023 Apr;58(2):433-444. doi: 10.1111/1475-6773.14116.Gao T, Wang XC, Chen R, Ngo HH, Guo W. Disability adjusted life year (DALY): a useful tool for quantitative assessment of environmental pollution. Sci Total Environ. 2015 Apr 1;511:268-87. doi: 10.1016/j.scitotenv.2014.11.048.Gao T, Wang XC, Chen R, Ngo HH, Guo W. Disability adjusted life year (DALY): a useful tool for quantitative assessment of environmental pollution. Sci Total Environ. 2015 Apr 1;511:268-87. doi: 10.1016/j.scitotenv.2014.11.048.Braveman P, Gottlieb L. The social determinants of health: it's time to consider the causes of the causes. Public Health Rep. 2014 Jan-Feb;129 Suppl 2(Suppl 2):19-31. doi: 10.1177/00333549141291S206.Braveman P, Gottlieb L. The social determinants of health: it's time to consider the causes of the causes. Public Health Rep. 2014 Jan-Feb;129 Suppl 2(Suppl 2):19-31. doi: 10.1177/00333549141291S206.The Health Foundation. Relationship between living standards and health. https://www.health.org.uk/evidence-hub/money-and-resources/persistent-poverty/relationship-between-living-standards-and-health (2022).The Health Foundation. Relationship between living standards and health. https://www.health.org.uk/evidence-hub/money-and-resources/persistent-poverty/relationship-between-living-standards-and-health (2022).American Society of Hematology. Milestones in Anticoagulant Drugs. https://www.hematology.org/about/history/50-years/milestones-anticoagulant-drugs (2008).American Society of Hematology. Milestones in Anticoagulant Drugs. https://www.hematology.org/about/history/50-years/milestones-anticoagulant-drugs (2008).American Society of Hematology. Antithrombotic Therapy. https://www.hematology.org/about/history/50-years/antithrombotic-therapy#:~:text=Anticoagulant (2008).American Society of Hematology. Antithrombotic Therapy. https://www.hematology.org/about/history/50-years/antithrombotic-therapy#:~:text=Anticoagulant (2008).Heestermans M, Poenou G, Hamzeh-Cognasse H, Cognasse F, Bertoletti L. Anticoagulants: A Short History, Their Mechanism of Action, Pharmacology, and Indications. Cells. 2022 Oct 13;11(20):3214. doi: 10.3390/cells11203214.Heestermans M, Poenou G, Hamzeh-Cognasse H, Cognasse F, Bertoletti L. Anticoagulants: A Short History, Their Mechanism of Action, Pharmacology, and Indications. Cells. 2022 Oct 13;11(20):3214. doi: 10.3390/cells11203214.Chen A, Stecker E, A Warden B. Direct Oral Anticoagulant Use: A Practical Guide to Common Clinical Challenges. J Am Heart Assoc. 2020 Jul 7; 9(13):e017559. doi: 10.1161/JAHA.120.017559.Chen A, Stecker E, A Warden B. Direct Oral Anticoagulant Use: A Practical Guide to Common Clinical Challenges. J Am Heart Assoc. 2020 Jul 7; 9(13):e017559. doi: 10.1161/JAHA.120.017559.Centers for Medicare and Medicaid Services. Medicare Current Beneficiary Survey. https://www.cms.gov/data-research/research/medicare-current-beneficiary-survey (2024).Centers for Medicare and Medicaid Services. Medicare Current Beneficiary Survey. https://www.cms.gov/data-research/research/medicare-current-beneficiary-survey (2024).Centers for Medicare and Medicaid Services. Medicare Current Beneficiary Survey. https://www.cms.gov/data-research/research/medicare-current-beneficiary-survey (2024).Centers for Medicare and Medicaid Services. Medicare Current Beneficiary Survey. https://www.cms.gov/data-research/research/medicare-current-beneficiary-survey (2024).RAND. Burden of Health Care Payments Is Greatest Among Americans with the Lowest Incomes. (2020).RAND. Burden of Health Care Payments Is Greatest Among Americans with the Lowest Incomes. (2020).Centers for Disease Control and Prevention, National Center for Health Statistics. National Vital Statistics System, Mortality 2018-2022 on CDC WONDER Online Database, released in 2024. Data are from the Multiple Cause of Death Files, 20182022, as compiled from data provided by the 57 vital statistics jurisdictions through the Vital Statistics Cooperative Program. Accessed at http://wonder.cdc.gov/ucd-icd10-expanded.html on May 1, 2024.Centers for Disease Control and Prevention, National Center for Health Statistics. National Vital Statistics System, Mortality 2018-2022 on CDC WONDER Online Database, released in 2024. Data are from the Multiple Cause of Death Files, 20182022, as compiled from data provided by the 57 vital statistics jurisdictions through the Vital Statistics Cooperative Program. Accessed at http://wonder.cdc.gov/ucd-icd10-expanded.html on May 1, 2024.Wang J, Geng L. Effects of Socioeconomic Status on Physical and Psychological Health: Lifestyle as a Mediator. Int J Environ Res Public Health. 2019 Jan 20;16(2):281. doi: 10.3390/ijerph16020281.Wang J, Geng L. Effects of Socioeconomic Status on Physical and Psychological Health: Lifestyle as a Mediator. Int J Environ Res Public Health. 2019 Jan 20;16(2):281. doi: 10.3390/ijerph16020281.Barakat C, Konstantinidis T. A Review of the Relationship between Socioeconomic Status Change and Health. Int J Environ Res Public Health. 2023 Jun 29;20(13):6249. doi: 10.3390/ijerph20136249.Barakat C, Konstantinidis T. A Review of the Relationship between Socioeconomic Status Change and Health. Int J Environ Res Public Health. 2023 Jun 29;20(13):6249. doi: 10.3390/ijerph20136249.Kornej J, Börschel CS, Benjamin EJ, Schnabel RB. Epidemiology of Atrial Fibrillation in the 21st Century: Novel Methods and New Insights. Circ Res. 2020 Jun 19;127(1):4-20. doi: 10.1161/CIRCRESAHA.120.316340.Kornej J, Börschel CS, Benjamin EJ, Schnabel RB. Epidemiology of Atrial Fibrillation in the 21st Century: Novel Methods and New Insights. Circ Res. 2020 Jun 19;127(1):4-20. doi: 10.1161/CIRCRESAHA.120.316340.Hart RG, Palacio S, Pearce LA. Atrial fibrillation, stroke, and acute antithrombotic therapy: analysis of randomized clinical trials. Stroke. 2002 Nov;33(11): 2722-7. doi: 10.1161/01.str.0000035735.49388.4a.Hart RG, Palacio S, Pearce LA. Atrial fibrillation, stroke, and acute antithrombotic therapy: analysis of randomized clinical trials. Stroke. 2002 Nov;33(11): 2722-7. doi: 10.1161/01.str.0000035735.49388.4a.Lee SR, Choi EK, Kwon S, Han KD, Jung JH, Cha MJ, Oh S, Lip GYH. Effectiveness and Safety of Contemporary Oral Anticoagulants Among Asians With Nonvalvular Atrial Fibrillation. Stroke. 2019 Aug;50(8):2245-2249. doi: 10.1161/STROKEAHA.119.025536.Lee SR, Choi EK, Kwon S, Han KD, Jung JH, Cha MJ, Oh S, Lip GYH. Effectiveness and Safety of Contemporary Oral Anticoagulants Among Asians With Nonvalvular Atrial Fibrillation. Stroke. 2019 Aug;50(8):2245-2249. doi: 10.1161/STROKEAHA.119.025536.McIntyre WF, Benz AP, Becher N, Healey JS, Granger CB, Rivard L, Camm AJ, Goette A, Zapf A, Alings M, Connolly SJ, Kirchhof P, Lopes RD. Direct Oral Anticoagulants for Stroke Prevention in Patients With Device-Detected Atrial Fibrillation: A Study-Level Meta-Analysis of the NOAH-AFNET 6 and ARTESiA Trials. Circulation. 2024 Mar 26;149(13):981-988. doi: 10.1161/CIRCULATIONAHA.123.067512.McIntyre WF, Benz AP, Becher N, Healey JS, Granger CB, Rivard L, Camm AJ, Goette A, Zapf A, Alings M, Connolly SJ, Kirchhof P, Lopes RD. Direct Oral Anticoagulants for Stroke Prevention in Patients With Device-Detected Atrial Fibrillation: A Study-Level Meta-Analysis of the NOAH-AFNET 6 and ARTESiA Trials. Circulation. 2024 Mar 26;149(13):981-988. doi: 10.1161/CIRCULATIONAHA.123.067512.Мусина Н.З., Федяева В.К. Методы расчета QALY как интегрального показателя эффективности в процессе комплексной оценки лекарственных препаратов. Фармакоэкономика. Современная фармакоэкономика и фармакоэпидемиология. 2017;10(1):66-71. https:// doi.org/10.17749/2070-4909.2017.10.1.066-071Musina N.Z., Fedyaeva V.K. The use of QALY as an integral measure of effectiveness in the evaluation of medical technologies. Farmakoekonomika. Modern Pharmacoeconomics and Pharmacoepidemiology. 2017;10(1):66-71. (In Russ.)].Колбин А.С., Влодавец Д.В., Курылев А.А., Балыкина Ю.Е., Проскурин М.А., Мишинова С.А., Германенко О.Ю., Колбина Н.Ю. Анализ социально-экономического бремени спинальной мышечной атрофии в Российской Федерации. Фармакоэкономика. Современная фармакоэкономика и фармакоэпидемиология. 2020;13(4):337354. https://doi.org/10.17749/2070-4909/farmakoekonomika.2020.068Kolbin A.S., Vlodavets D.V., Kurylev A.A., Balykina Yu.Ye., Proskurin M.A., Mishinova S.A., Germanenko O.Yu., Kolbina N Yu. The social-economic burden of spinal muscular atrophy in Russia. Farmakoekonomika. Modern Pharmacoeconomics and Pharmacoepidemiology. 2020;13(4):337-354. (In Russ.)].Гомон Ю.М., Стрижелецкий В.В., Иванов И.Г., Балыкина Ю.Е., Ермольев М.В., Колбин А.С., Лившиц М.В., Усманова Т.А., Фахрутдинова А.М., Константинова Ю.С., Губанов А.П. Эффективность применения левилимаба у пациентов со среднетяжелым и тяжелым течением COVID-19. Фармакоэкономика. Современная фармакоэкономика и фармакоэпидемиология. 2023;16(1):36–47. https://doi.org/10.17749/2070-4909/farmakoekonomika.2023.164Gomon Yu.M., Strizheletsky V.V., Ivanov I.G., Balykina Yu.E., Ermolyev M.V., Kolbin A.S., Livshits M.V., Usmanova T.A., Fakhrutdinova A.M., Konstantinova Yu.S., Gubanov A.P. Efficiency of Levilimab in patients with moderate and severe COVID-19. Farmakoekonomika. Modern Pharmacoeconomics and Pharmacoepidemiology. 2023;16(1):36–47. (In Russ.)].

The authors declare that there are no conflicts of interest present.